Details

Autor(en) / Beteiligte

• Bairey Merz, C. Noel, MD, FACC, FAHA
• Alberts, Mark J., MD, FAHA
• Balady, Gary J., MD, FACC
• Ballantyne, Christie M., MD, FACC
• Berra, Kathy, MSN, ANP, FAHA, FAAN
• Black, Henry R., MD
• Blumenthal, Roger S., MD, FACC, FAHA
• Davidson, Michael H., MD, FACC
• Fazio, Sara B., MD
• Ferdinand, Keith C., MD, FACC, FAHA
• Fine, Lawrence J., MD, DrPH
• Fonseca, Vivian, MD
• Franklin, Barry A., PhD, FAHA
• McBride, Patrick E., MD, MPH, FACC, FAHA
• Mensah, George A., MD, FACC, FACP, FAHA
• Merli, Geno J., MD, FACP
• O'Gara, Patrick T., MD, FACC, FAHA
• Thompson, Paul D., MD, FACC
• Underberg, James A., MD, MS, FACPM, FACP

Titel

ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease

Ist Teil von

• Journal of the American College of Cardiology, 2009-09, Vol.54 (14), p.1336-1363

Ort / Verlag

New York: Elsevier Inc

Erscheinungsjahr

2009

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• [...]a new and growing knowledge base of molecular genetics applied to the study of the cardiovascular system has potential relevance to the clinical practice of preventive cardiovascular medicine. The prevention of cardiovascular morbidity and mortality is a shared responsibility among all health professionals involved in the care of people at risk of developing CVD.\n Ken Uchino Organizational Reviewer--American Academy of Neurology None None None None None None Dr. Vera Bittner Organizational Reviewer--American Association of Cardiovascular and Pulmonary Rehabilitation Abbott Laboratories CV Therapeutics, Inc. Pfizer, Inc. Reliant Pharma., LLP None None Atherogenics* CV Therapeutics, Inc.* Merck Research Labs* National Institutes of Health/Abbott* Pfizer, Inc.* None None Dr. Randal J. Thomas Organizational Reviewer--American Association of Cardiovascular and Pulmonary Rehabilitation None None None Omron, Inc.* None None Dr. W. Fred Miser Organizational Reviewer--American College of Preventive Medicine Actelion* CoTherix* Encysive Pfizer United Therapeutics Actelion* Pfizer None Actelion* CoTherix* Encysive* Pfizer* United Therapeutics* None Diet drug litigation Dr. Curt D. Furberg Organizational Reviewer--American Diabetes Association None None None None None None Dr. Silvio Inzucchi Organizational Reviewer--American Diabetes Association None None None None None None Dr. George L. Bakris Organizational Reviewer--American Society of Hypertension Abbott Laboratories Boehringer Ingelheim Corp. Bristol-Myers Squibb/SanofiPharma Daiichi/Sankyo, Inc. Forest Laboratories Gilead GlaxoSmithKline Merck & Co., Inc. Novartis Pharma. Walgreens None GlaxoSmithKline* Forest Laboratories* National Institutes of Health (NIDDK/NHLBI)* None None Dr. Michael S. Lauer Organizational Reviewer--National Heart, Lung, and Blood Insitute None None None None None None Ms. Janet B. Long Organizational--National Lipid Association None AstraZeneca None None None None Dr. Peter Wilson Organizational--National Lipid Association None None None GlaxoSmithKline* Sanofi-Aventis* None None Dr. Lynne T. Braun Organizational--Preventive Cardiovascular Nurses Association AstraZeneca diaDexus None None None None None Ms. Joanna Sikkema Organizational--Preventive Cardiovascular Nurses Association None None None None None None Dr. Vera Bittner Content Reviewer--ACCF Prevention Committee Abbott Laboratories CV Therapeutics, Inc. Pfizer, Inc. Reliant Pharma., LLP None None Atherogenics* CV Therapeutics, Inc.* Merck Research Labs* NIH/Abbott* Pfizer, Inc.* None None Dr. Gregg C. Fonarow Content Reviewer--ACCF Prevention Committee AstraZeneca Bristol-Myers Squibb GlaxoSmithKline* Merck/Schering-Plough* Novartis Pharma* Pfizer, Inc.* None None GlaxoSmithKline* Pfizer, Inc.* None None Dr. Pamela B. Morris Content Reviewer--ACCF Prevention Committee Actelion[dagger] None None None None None Dr. Ileana L. Piña Content Reviewer--ACCF/AHA/ACP Task Force on Competence and Training GlaxoSmithKline AstraZeneca Novartis None None None None Dr. Howard H. Weitz Content Reviewer--ACCF/AHA/ACP Task Force on Competence and Training None None None None None None * This table represents the relevant relationships with industry and other entities that were disclosed at the time of peer review.